Sun Pharma Advanced Research Company Limited — Important, 03-06-2025: General Updates

SPARC’s partner Sun Pharma reported Phase 2 trials for Vibozilimod (SCD-044) in moderate-to-severe psoriasis and atopic dermatitis did not meet key efficacy goals, showing under 75% improvement at Week 16. This setback puts the drug’s development timeline at risk and could affect its future value potential. SPARC and Sun Pharma will reassess the program moving forward.